Skip to main content

Regional citrate anticoagulation with a low-concentration solution in predilution-postdilution CVVH


Systemic anticoagulation (AC) can increase the bleeding risk in CRRT. However, regional citrate anticoagulation (RCA) is a valid alternative to heparin (Hep) in patients at high risk of bleeding. The aim was to evaluate efficacy and safety of RCA-CVVH using a low-concentration citrate (Citr) solution.


In cardiac surgery patients with AKI we adopted RCA-CVVH as an alternative to Hep or no-AC CRRT. Criteria for switching to RCA: early circuit clotting (24 hours) or Hep-related complications. RCA-CVVH was performed with a predilution Citr solution (12 mmol/l) and a postdilution hemofiltration solution (HCO3- 32 mEq/l). In relation to blood flow rate (Qb), the Citr solution rate was set to meet a circuit Citr concentration of 3 mmol/l and modified to obtain circuit Ca2+ < 0.4 mmol/l. CaCl2 (10%) was infused to maintain systemic Ca2+ (s-Ca2+) of 1.1 to 1.25 mmol/l. To facilitate CVVH settings, we developed a mathematical model to estimate the metabolic Citr load, buffer balance and Ca2+ loss.


In 30 patients at high bleeding risk (age 70.5 ± 9.3, SOFA score 13.7 ± 2.5) the AC modality was switched to RCA-CVVH from no AC or Hep. CVVH initial settings: dialysis dose 33.6 ± 3.4 ml/kg/hour; Qb 135 ± 14 ml/minute; Q Citr 1,703 ± 250 ml/hour; Q postdilution 761 ± 181 ml/hour; Citr load 11.6 ± 2.1 mmol/hour; CaCl2 3.7 ± 1.5 ml/hour. Target circuit Ca2+ and s-Ca2+ were maintained (0.37 ± 0.09 and 1.18 ± 0.13 mmol/l) with few modifications of Citr and CaCl2 infusion rates. We used 146 RCA-CVVH circuits with filter life 50.5 ± 35.8 hours (median 41; total 7,372). RCA-stopping causes: 34% CVC malfunction, 24% alarm handling/technical issues, 20% scheduled, 14% medical procedures, 8% others. Before starting RCA, we used 69 Hep circuits (2,015 hours) and 74 no-AC circuits (1,827 hours) with a filter life of 29.2 ± 20.7 hours (median 22) and 24.7 ± 20.6 hours (median 20), shorter than RCA (P < 0.0001). Circuits running at 24, 48 and 72 hours (%): RCA 73, 42 and 28; Hep 43, 23 and 10; and no-AC 38, 12 and 5 (log-rank test P < 0.0001). During RCA-CVVH no patients had bleeding complications and the transfusion rate was lower if compared to other AC modalities (0.29 vs. 0.69 blood units/day, P = 0.001). PLT count (P = 0.018) and AT-III activity (P = 0.009) increased throughout days of RCA, reducing supplementation needs. RCA has been stopped for Citr accumulation in one patient (calcemia/s-Ca2+ >2.5).


In this experience, RCA allowed one to safely prolong the filter life, decreasing the transfusion rate and supplementation needs for AT-III and PLT. The use of a mathematical model allowed one to simplify the CVVH settings. Therefore, RCA should be worthy of more consideration as the first-choice CRRT AC modality in patients at high risk of bleeding.

Author information



Corresponding author

Correspondence to V Pistolesi.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Pistolesi, V., Morabito, S., Tritapepe, L. et al. Regional citrate anticoagulation with a low-concentration solution in predilution-postdilution CVVH. Crit Care 16, P367 (2012).

Download citation


  • Bleeding Risk
  • Transfusion Rate
  • Citr Solution
  • Regional Citrate Anticoagulation
  • Dialysis Dose